COLLINS HELEN LOUISE (CHIEF MEDICAL OFFICER) sold 16.7% of their position (5K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $263.4K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
+5K
Price / share
$2.48
Trade value
$12.40K
% of position
Common Stock
Shares
−231.00
Price / share
$50.05
Trade value
$11.56K
% of position
Common Stock
Shares
−459.00
Price / share
$51.55
Trade value
$23.66K
% of position
Common Stock
Shares
−2.06K
Price / share
$52.39
Trade value
$108.08K
% of position
Common Stock
Shares
−2.18K
Price / share
$53.42
Trade value
$116.67K
% of position
Common Stock
Shares
−63.00
Price / share
$53.92
Trade value
$3.40K
% of position
Net shares
+0.00
Net value
-$250.97K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 7/17/2026 | M · Option Exercise | +5K | $2.48 | $12.40K | 20.0% | 25K | 30K |
| Common Stock Direct | 7/17/2026 | S · Sale | −231.00 | $50.05 | $11.56K | 0.8% | 30K | 29.77K |
| Common Stock Direct | 7/17/2026 | S · Sale | −459.00 | $51.55 | $23.66K | 1.5% | 29.77K | 29.31K |
| Common Stock Direct | 7/17/2026 | S · Sale | −2.06K | $52.39 | $108.08K | 7.0% | 29.31K | 27.25K |
| Common Stock Direct | 7/17/2026 | S · Sale | −2.18K | $53.42 | $116.67K | 8.0% | 27.25K | 25.06K |
| Common Stock Direct | 7/17/2026 | S · Sale | −63.00 | $53.92 | $3.40K | 0.3% | 25.06K | 25K |
| Total | +0.00 | -$250.97K | ||||||
Stock Option (right to buy)
Common Stock
5K shares
Shares
−5K
Strike price
2.48
Held after
116.27K
Exercisable
—
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) Direct | Common Stock5K shares | 7/17/2026 | M · Option Exercise | −5K | 2.48 | — | 116.27K |